Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous BIBN 4096 BS in Healthy Volunteers
NCT02194348Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2000
- Primary completion
- Mar 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing BIBN 4096 BS with Placebo (2 arms). Primary endpoints: Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate), Number of patients with clinically significant changes in 12-lead Electrocardiogram (ECG) and 2 more. Started Feb 2000; status: completed.
02
Drugs
olcegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02194348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194348.